查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
北美传染病分子诊断市场预测至 2030 年 - 区域分析 - 按类型（护理点检测和实验室检测）、最终用户、应用、疾病类型、感染类型
市场调查报告书
商品编码
1494288

北美传染病分子诊断市场预测至 2030 年 - 区域分析 - 按类型（护理点检测和实验室检测）、最终用户、应用、疾病类型、感染类型

North America Molecular Diagnostics for Infectious Disease Market Forecast to 2030 - Regional Analysis - by Type (Point-of-Care Testing and Laboratory Testing), End User, Application, Disease Type, Infection Type
出版日期: | 出版商: The Insight Partners | 英文 108 Pages | 订单完成后即时交付

价格

2022年北美传染病分子诊断市值为33.4515亿美元，预计2030年将达到84.197亿美元；预计2022年至2030年复合年增长率为12.2%。

个人化医疗中的传染病分子诊断推动了北美传染病分子诊断市场

随着高通量技术的进步，基因组研究变得更加方便和具有成本效益。分子诊断在临床实验室中变得越来越不可或缺，因为这些试剂盒和测试可以提供快速的检测结果，而传统测试则需要在少数情况下在实验室条件下培养微生物。根据每位患者独特的基因组成、生活方式和环境，使用精准医学为每位患者量身定制医疗治疗和介入措施。分子诊断在这种方法中发挥重要作用，因为它能够识别影响患者治疗相关决策的特定生物标记、基因突变和基因表现模式。药物开发越来越依赖分子诊断。各种分子影像技术用于筛检、检测、诊断、治疗和评估异质性，以製定进展计划、检查分子特征和监测患者结果。个人化医疗通常旨在询问患者的基因组信息，例如药物代谢多态性有助于指导药物选择和剂量。在传染病中，个人化医学概念可用于快速识别致病微生物，确定其抗菌药物抗药性，并根据结果确定适当的抗菌治疗，以便对患者进行适当的管理。传染病的即时检测需要医疗当局的认可、新技术和通讯平台的开发以及报销政策，以便最大数量的患者能够从挽救生命和节省时间的程序中受益。将这些技术引入临床实践将能够识别每个患者的分子标靶，并有助于追踪疾病的分子进展。

因此，随着技术的不断发展，传染病分子诊断市场似乎有着光明的前景。

北美传染病分子诊断市场概述

墨西哥结核病（TB）盛行率的不断上升以及结核病诊断和治疗意识的提高正在推动传染病分子诊断市场的成长。根据 StopTB Partnership Organization 的数据，结核病的人数从 2019 年的 30,000 人增加到 2020 年的 31,000 人。这些项目包括墨西哥索诺拉州和下加利福尼亚州检测药物敏感和抗药性结核病病例的两个项目。这两个计画的共同目标是建立州和国家疾病控制计画的能力，以识别高风险族群并对该族群进行快速结核病检测。这些针对群众进行结核病筛检的措施正在提高墨西哥民众的意识。此外，製药业的广泛发展、医疗保健基础设施的发展以及对诊断测试产品的需求不断增加，都促进了墨西哥传染病分子诊断市场的成长。 2021 年 2 月，世界卫生组织 (WHO) 宣布在儿童、青少年和成人的结核病和抗药性诊断方面取得重大进展。宣布的三类新用于检测结核病的新技术如下：

  • 用于诊断结核病并检测利福平和异烟肼抗药性变异体的中等复杂度自动化核酸扩增测试 (NAAT)
  • 用于检测异烟肼和二线抗结核药物抗药性的低复杂性自动化 NAAT
  • 基于高复杂性杂交的 NAAT，用于检测吡嗪酰胺抗药性。

北美传染病分子诊断市场收入及 2030 年预测（百万美元）

北美传染病分子诊断市场区隔

北美传染病分子诊断市场根据类型、最终用户、应用、疾病类型、感染类型和国家进行细分。

根据类型，北美传染病分子诊断市场分为即时检测和实验室检测。到2022年，实验室检测领域将占据北美传染病分子诊断市场更大的市场份额。

北美传染病分子诊断市场依最终用户划分，分为现场检测和实验室检测。现场护理测试进一步分为人体测试和兽医测试。同样，实验室测试进一步分为人体测试和兽医测试。到 2022 年，人体检测领域（按现场检测）将占据更大的北美传染病分子诊断市场。疾病市场占有率。

根据应用，北美传染病分子诊断市场分为即时检测和实验室检测。即时检测进一步细分为单一病原体的检测、两种或多种病原体的检测、新出现的新型感染的评估、生物威胁製剂和疾病相关生物标记的监测和早期检测以及抗菌素抗药性分析。同样，实验室检测进一步分为患者分层、药物治疗方案选择、毒性避免、治疗监测和疾病易感性检测。到 2022 年，透过现场检测进行单一病原体检测，占据北美最大的传染病分子诊断市场。份额。

根据疾病类型，北美传染病分子诊断市场分为即时检测和实验室检测。护理点检测进一步细分为败血症（例如泌尿生殖系统/肺/伤口）、假体关节感染、心内膜炎、性病、单核细胞增多症、A 型链球菌等。同样，实验室检测进一步分为败血症、人工关节感染、心内膜炎、性传染病、披衣菌、胃肠道感染、结核、H1N1病毒等。以床边检测计算，STD 细分市场将在2022 年占据北美最大的传染病分子诊断市场。份额。

根据感染类型，北美传染病分子诊断市场分为即时检测和实验室检测。即时检测进一步细分为细菌、病毒、真菌等。同样，实验室检测进一步分为细菌、病毒、真菌等。根据即时检测，细菌细分市场将在 2022 年占据北美最大的传染病分子诊断市场。年。

依国家划分，北美传染病分子诊断市场分为美国、加拿大和墨西哥。 2022年，美国将主导北美传染病分子诊断市场。

Abbott Laboratories、bioMerieux SA、Bruker Corp、Danaher Corp、DiaSorin SpA、F. Hoffmann-La Roche Ltd、Hologic Inc、Siemens Healthineers AG 和 Thermo Fisher Scientific Inc 是北美传染病分子诊断领域的一些领先公司疾病市场。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解
  • 北美传染病分子诊断市场，依国家、市场吸引力

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美传染病分子诊断市场 - 主要产业动态

  • 市场驱动因素：
    • 全球传染病发生率激增
    • 分子诊断在兽医传染病的应用不断增加
  • 市场限制
    • 与分子测试相关的局限性
  • 市场机会
    • 分子诊断技术的进步
  • 未来的趋势
    • 个人化医疗中传染病的分子诊断
  • 影响分析：

第 5 章：传染病分子诊断市场 - 北美市场分析

  • 北美传染病分子诊断市场收入，2022 - 2030

第 6 章：北美传染病分子诊断市场 - 收入和 2030 年预测 - 按类型

  • 概述
  • 北美传染病分子诊断市场收入份额（按类型），2022 年和 2030 年（%）
  • 即时检测
  • 实验室测试

第 7 章：北美传染病分子诊断市场 - 收入和 2030 年预测 - 按最终用户

  • 概述
  • 北美传染病分子诊断市场收入份额（按最终用户分類的即时检测和实验室检测），2022 年和 2030 年（%）

第 8 章：北美传染病分子诊断市场 - 收入和 2030 年预测 - 按应用

  • 概述
  • 2022 年和 2030 年按应用分類的传染病分子诊断市场收入份额（按应用划分）（%）
  • 即时检测
  • 实验室测试

第 9 章：北美传染病分子诊断市场 - 收入和 2030 年预测 - 按疾病类型

  • 概述
  • 北美传染病分子诊断市场收入份额（按疾病类型分類的即时检测），2022 年和 2030 年（%）
  • 即时检测
  • 实验室测试

第 10 章：北美传染病分子诊断市场 - 收入和 2030 年预测 - 按感染类型

  • 概述
  • 北美传染病分子诊断市场收入份额（按感染类型分類的即时检测），2022 年和 2030 年（%）
  • 即时检测
  • 实验室测试

第 11 章：北美传染病分子诊断市场 - 国家分析

  • 我们
  • 加拿大
  • 墨西哥

第 12 章：产业格局

  • 概述
  • 市场上公司采取的成长策略，(%)
  • 有机发展
    • 概述
  • 无机发展
    • 概述

第 13 章：公司简介

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • bioMerieux SA
  • Danaher Corp
  • Hologic Inc
  • Siemens Healthineers AG
  • Bruker Corp
  • DiaSorin SpA

第 14 章：附录

Product Code: BMIRE00029839

The North America molecular diagnostics for infectious disease market was valued at US$ 3,345.15 million in 2022 and is expected to reach US$ 8,419.70 million by 2030; it is estimated to grow at a CAGR of 12.2% from 2022 to 2030.

Molecular Diagnostics for Infectious Diseases in Personalized Medicine Fuels the North America Molecular Diagnostics for Infectious Disease Market

Genome research has become more convenient and cost-effective with progress in high-throughput techniques. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to conventional tests, which involve culturing microbes in laboratory conditions in a few cases. Medical treatments and interventions are tailored to each patient using precision medicine based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. Various molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity to make progression plans, examine molecular characteristics, and monitor patient outcomes. Personalized medicine generally aims to interrogate the genomic information of a patient, e.g., drug metabolism polymorphisms help guide drug choice and dosage. In infectious diseases, personalized medicine concepts can be used to rapidly identify disease-causing microorganisms, determine their antimicrobial resistance profiles, and ascertain an appropriate antimicrobial treatment for the proper management of the patient based on the results. Point-of-care testing for infectious diseases requires the acceptance of medical authorities, development of new technology and communication platforms, and reimbursement policies so that the greatest number of patients can benefit from lifesaving and time-saving procedures. Introducing these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases.

Thus, with ever-evolving technology, the market for molecular diagnostics for infectious diseases seems to have a bright future.

North America Molecular Diagnostics for Infectious Disease Market Overview

The increasing prevalence of tuberculosis (TB) and rise in awareness of diagnosis and treatment for TB in Mexico is fueling the growth of the molecular diagnosis for infectious diseases market. According to StopTB Partnership Organization, the number of people suffering from TB rose from 30,000 in 2019 to 31,000 in 2020. The growing focus of Centers for Disease Control and Prevention (CDC) has established several international laboratory projects in Mexico. These projects include two projects for the detection of drug-sensitive and drug-resistant TB cases in Sonora and Baja California, Mexico. The common goal of these two projects is to build capacity for state and national disease control program to identify the group at risk and conduct rapid TB tests on that group. These initiatives for screening the masses for TB are creating awareness in the Mexican population. In addition, the extensively growing pharmaceuticals industry, developing healthcare infrastructure, and elevating demand for diagnostic testing products bolster the molecular diagnostics for infectious diseases market growth in Mexico. In February 2021, the World Health Organization (WHO) announced significant advancements in the diagnosis of TB and drug resistance in children, adolescents, and adults. The three new classes of technologies announced for testing TB were as follows:

  • Moderate-complexity automated Nucleic Acid Amplification Tests (NAATs) for the diagnosis of TB and detection of variants resistant to rifampicin and isoniazid
  • Low-complexity automated NAATs for detection of resistance to isoniazid and second-line anti-TB agents
  • High-complexity hybridization-based NAATs for the detection of resistance to pyrazinamide.

North America Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)

North America Molecular Diagnostics for Infectious Disease Market Segmentation

The North America molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.

Based on type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger North America molecular diagnostics market for infectious disease market share in 2022.

The North America molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger North America molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger North America molecular diagnostics market for infectious disease market share in 2022.

Based on application, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.

Based on disease type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.

Based on infection type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.

Based on country, the North America molecular diagnostics for infectious disease market is categorized into the US, Canada, and Mexico. The US dominated the North America molecular diagnostics for infectious disease market in 2022.

Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America molecular diagnostics for infectious disease market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 North America Molecular Diagnostic for Infectious Diseases Market, by Country, Market attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Molecular Diagnostic for Infectious Diseases Market - Key Industry Dynamics

  • 4.1 Market Drivers:
    • 4.1.1 Surging Prevalence of Infectious Disease Globally
    • 4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
  • 4.2 Market Restraints
    • 4.2.1 Limitations Associated with Molecular Testing
  • 4.3 Market Opportunities
    • 4.3.1 Advancements in Molecular Diagnostics Technologies
  • 4.4 Future Trends
    • 4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
  • 4.5 Impact Analysis:

5. Molecular Diagnostic for Infectious Diseases Market - North America Market Analysis

  • 5.1 North America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 - 2030

6. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Type

  • 6.1 Overview
  • 6.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
  • 6.3 Point-of-Care Testing
    • 6.3.1 Overview
    • 6.3.2 Point-of-Care Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Laboratory Testing
    • 6.4.1 Overview
    • 6.4.2 Laboratory Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by End User

  • 7.1 Overview
  • 7.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
    • 7.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    • 7.2.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)

8. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Application

  • 8.1 Overview
  • 8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
  • 8.3 Point-of-Care Testing
    • 8.3.1 Overview
    • 8.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
  • 8.4 Laboratory Testing
    • 8.4.1 Overview
    • 8.4.2 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)

9. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Disease Type

  • 9.1 Overview
  • 9.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
  • 9.3 Point-of-Care Testing
    • 9.3.1 Overview
    • 9.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
      • 9.3.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
  • 9.4 Laboratory Testing
    • 9.4.1 Overview
    • 9.4.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
      • 9.4.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)

10. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Infection Type

  • 10.1 Overview
  • 10.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
  • 10.3 Point-of-Care Testing
    • 10.3.1 Overview
    • 10.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
  • 10.4 Laboratory Testing
    • 10.4.1 Overview
    • 10.4.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)

11. North America Molecular Diagnostic for Infectious Diseases Market - Country Analysis

  • 11.1 North America Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast To 2030
    • 11.1.1 Overview
    • 11.1.2 North America Molecular Diagnostic for Infectious Diseases Market, by Country
      • 11.1.2.1 US
        • 11.1.2.1.1 US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.1.2 US: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.1.3 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.1.4 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.1.5 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.1.6 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.1.7 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.1.7.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.1.8 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.1.8.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.1.9 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.1.10 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.2 Canada
        • 11.1.2.2.1 Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.2.2 Canada: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.2.3 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.2.4 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.2.5 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.2.6 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.2.7 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.2.7.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.2.8 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.2.8.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.2.9 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.2.10 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
      • 11.1.2.3 Mexico
        • 11.1.2.3.1 Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
        • 11.1.2.3.2 Mexico: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
        • 11.1.2.3.3 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.3.4 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
        • 11.1.2.3.5 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.3.6 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
        • 11.1.2.3.7 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.3.7.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
        • 11.1.2.3.8 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
        • 11.1.2.3.8.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
        • 11.1.2.3.9 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
        • 11.1.2.3.10 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies Done by the Companies in the Market, (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Abbott Laboratories
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Thermo Fisher Scientific Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 bioMerieux SA
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Danaher Corp
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Hologic Inc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Siemens Healthineers AG
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Bruker Corp
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 DiaSorin SpA
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. North America Molecular Diagnostic for Infectious Diseases Market Segmentation
  • Table 2. North America Molecular Diagnostic for Infectious Diseases Market, for Point of Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. US Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. US Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. US Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 21. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. Canada Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 25. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 26. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 27. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 29. Canada Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 30. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 31. Canada Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 33. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 34. Mexico Molecular Diagnostic for Infectious Diseases Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 35. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 36. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 37. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 38. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 39. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 40. Mexico Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 41. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 42. Mexico Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing - Revenue and Forecast to 2030 (US$ Million)
  • Table 43. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 44. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 45. Organic Developments Done By Companies
  • Table 46. Inorganic Developments Done By Companies
  • Table 47. Glossary of Terms, Molecular Diagnostic for Infectious Diseases Market

List Of Figures

  • Figure 1. North America Molecular Diagnostic for Infectious Diseases Market Segmentation, By Country
  • Figure 2. North America Molecular Diagnostic for Infectious Diseases Market - Key Industry Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 - 2030
  • Figure 5. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
  • Figure 6. Point-of-Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Laboratory Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
  • Figure 9. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
  • Figure 10. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
  • Figure 11. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
  • Figure 12. North America: Molecular Diagnostic for Infectious Diseases Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 13. North America Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
  • Figure 14. US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 15. Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 16. Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 17. Growth Strategies Done by the Companies in the Market, (%)